- ► 2014 (24)
- ▼ December (2)
- ► October (6)
- ► 2012 (13)
Friday, 20 December 2013
Monday, 16 December 2013
Written by Brittani Baxter in our San Francisco Office
Friday, 1 November 2013
Alzheimer's insight from DNA study
Communicating diabetes to the online masses - how can pharma take advantage?
Monday, 28 October 2013
Friday, 25 October 2013
Read more: Ex-Bristol-Myers exec faces 1 year in prison for insider trading - FiercePharma http://www.fiercepharma.com/story/ex-bristol-myers-exec-faces-1-year-prison-insider-trading/2013-10-24#ixzz2ijNm55NK
Read more: FDA staffers tee up Gilead's hep C drug sofosbuvir for upbeat panel meeting - FiercePharma http://www.fiercepharma.com/story/fda-staffers-tee-gileads-hep-c-drug-sofosbuvir-upbeat-panel-meeting/2013-10-23#ixzz2ijOvvMHr
Thursday, 24 October 2013
One of the main questions: what caused those girls to act so strangely and spark the craze of paranoia that led to so many deaths? Many theories have been put forward throughout the centuries, mostly based on the assumption that the girls faked their illness either to fuel family rivalries or as a cruel prank.
In 1976, Linnda R. Carporael proposed a new hypothesis: that the girls were suffering from poisoning by ergot-tainted rye. Their symptoms cited in the trials – convulsion, hallucination, crawling sensations in the skin, tingling in the fingers, headaches, vomiting, diarrhea, mania, psychosis, and delirium – match that of ergotism. Moreover, there was an abundance of rye in the area and, during those years, the right weather conditions for ergot to flourish. Although this theory has been subject to some academic debate, it is still one of the most widely accepted reasons behind the seventeenth century hysteria.
Wednesday, 23 October 2013
Tuesday, 8 October 2013
Becky Geffen Graduate Research Executive
- BSc (Hons) Natural Sciences from Newcastle University majoring in medicinal chemistry
- MSc Pharmacology from Oxford University
- Research experience in anticancer drug design and the mechanisms of antibiotic resistance
Friday, 4 October 2013
This week's catch:
Thursday, 21 March 2013
It was recognised that non-adherence to treatment is under-evaluated and that it has a considerable financial impact. Some groups of patients are more likely than others to show poor adherence to treatments and adherence varies across treatments and therapy areas. There are many causes for the lack of adherence, which may leave physicians frustrated and/or powerless. The pharmaceutical industry may be able to help, by developing patient support materials and programs, that will be endorsed by the relevant healthcare professionals.
But beyond the execution and tools such as youtube videos and leaflets, we need to understand the underlying causes of non adherence as well as the key drivers for adherence. Understanding what drives adherence as well as what drives the lack of adherence will enable to develop strategies to encourage the right behaviour.
The short film below illustrates the various purposes of communication and how a better understanding of your audience will help shape stronger, more effective messages.
If you would like to learn more about patient adherence, the webinar is still available for members on the EPhMRA website. It discussed the definitions of patient adherence and why it is an important issue for the pharmaceutical industry. It also explored further the causes for poor adherence and commented on the current array of programs designed to improve adherence.
The author: Axel Rousseau is brand scientist at Branding-Science and has been working on international market research and consultancy since 2008.
Friday, 15 February 2013
In addition to the spot below, the campaign includes a series of testimonies from cancer patients and their relatives for a powerful call to action.
The author: Axel Rousseau is brand scientist (SRE) at Branding-Science and has been working on international market research and consultancy since 2008.